Background: Despite numerous design iterations, thrombus formation at the inflow cannula of continuous-flow left ventricular assist devices remains an unsolved problem. We systematically investigated the impact of cannula surface on thrombus formation.
Methods: Thrombus appearance was photographically documented in 177 explanted hearts with the polished (N = 46) or sintered (N = 131) inflow cannula of the Medtronic HeartWare™ HVAD™ System. Thrombus load was compared for both inflow cannula types. Mean thrombus length was correlated with protruding cannula length. Support duration and the extent of thrombus growth were examined. The prevalence of thrombi at the left ventricular entry site and at the sintered-to-polished transition zone was correlated with left ventricular geometry and hemodynamic parameters.
Results: Polished inflow cannulas showed a greater percentage and also a greater mean length of thrombus formation at the entry site than sintered cannulas (91.3% [Pol] vs. 36.7% [sTi]; p < 0.0001; mean 7.6 mm vs. 1.9 mm; p < 0.0001). A comparison of the early postoperative period (POD1-90) with long-term support (POD>90) showed an increase in thrombus length originating from the transition zone (1.96 ± 3.41 mm vs. 3.03 ± 2.91 mm; p = 0.013).
Conclusions: A sintered titanium surface at the entry site is crucial to enable anchoring of myocardial tissue to the cannula. As thrombus growth progresses on polished surfaces, a greater sintered length seems to be beneficial. After an initial three-month healing period, thrombus load appears to decline during prolonged support duration at the sintered entry site but not at the transition zone.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/aor.14222 | DOI Listing |
Indian J Ophthalmol
December 2024
Department of Oculoplasty, Disha Eye Hospitals Pvt Ltd, Kolkata, West Bengal, India.
JTCVS Open
October 2024
Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.
Objective: A less-invasive left atrial assist device (LAADx) is a novel and implantable, extracardiac blood pump concept, intended for the treatment of diastolic heart failure, represented by heart failure with preserved ejection fraction.
Methods: A mixed-flow pump was used as the working LAADx model. Its performance was evaluated at 3 speeds, using an in vitro pulsatile mock circulatory loop, with a pneumatic pump that can simulate diastolic heart failure conditions by adjusting the diastolic drive pressure.
Comput Methods Programs Biomed
December 2024
National Research Council, Institute of Clinical Physiology (IFC-CNR), 00185 Rome, Italy; Faculty of Medicine, Teaching University Geomedi, 0114 Tbilisi, Georgia. Electronic address:
Background And Objective: Right ventricular failure increases short-term mortality in the setting of acute myocardial infarction, cardiogenic shock, advanced left-sided heart failure and pulmonary arterial hypertension. Percutaneous and surgically implanted right ventricular assist devices (RVAD) have been investigated in different clinical settings. The use of the ProtekDuo™ is currently a promising approach due to its features such as groin-free approach leading to early mobilisation, easy percutaneous deployment, compatibility with different pumps and oxygenators, and adaptability to different configurations.
View Article and Find Full Text PDFEuropace
November 2024
Department of Cardiology and Vascular Medicine, University Hospital Frankfurt, Goethe-University Frankfurt, ZIM-Med. Klinik 3-Kardiologie, Angiologie, Frankfurt am Main, Germany.
Perfusion
September 2024
Department of Surgery, Division of Cardiothoracic Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, MO, USA.
Introduction: The Protek Duo (PtD) dual lumen, single cannula was developed as a percutaneous system for temporary mechanical support, inserted through the internal jugular vein (IJ) for both atrial inflow and pulmonary artery outflow. Outcomes of PtD compared to alternative Peripheral Right Ventricular Assist Device (pRVAD) methods are limited.
Methods: A retrospective analysis was conducted of pRVAD recipients from January 2017 - February 2022 ( = 111).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!